Benzinga | May 7, 2021 07:42AM EDT

Raymond James Downgrades ChemoCentryx to Outperform, Lowers Price Target to $51

Raymond James analyst Steven Seedhouse downgrades ChemoCentryx (NASDAQ:CCXI) from Strong Buy to Outperform and lowers the price target from $120 to $51.